Tscan Therapeutics is trading 6.21% down at $0.77 after an August 18, 2026 filing disclosed that Amgen elected to terminate its research collaboration and license agreement.
- Termination is effective November 10, 2026.
- Agreement included potential milestone payments exceeding $500 million and tiered royalties; Tscan does not expect to receive them unless certain products continue to be exploited.
- The decline was company-specific despite biotechnology-sector strength on August 19, 2026; no additional same-day company announcement was identified.